Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Hutchmed
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05093322CT.gov A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | — | Completed | — | — | — |
NCT04579757CT.gov Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Soft Tissue Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Surufatinib (this asset) | Hutchmed | P1/2 | CCC · 52 |
| Palbociclib | Brown University | P2 | BB |
| Nivestim | University of California, Irvine | P3 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Dacarbazine | Institut Bergonié | P3 | BB |
| Adriamycin | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P3 | BB |
| Irinotecan | GI Innovation, Inc. | P1/2 | BB |
| Olaparib | OHSU Knight Cancer Institute | P2 | BB |
| Tislelizumab | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BB |
+42 more in the Soft Tissue Sarcoma cohort
Other indications for Surufatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroendocrine Neoplasm | — | P3 | BB · 64 |
| Malignant Pancreatic Neoplasm | — | P3 | BB · 64 |
| Colorectal Cancer | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Surufatinib in Soft Tissue Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/surufatinib-soft-tissue-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →